Name (Synonyms) | Correlation | |
---|---|---|
drug166 | Anakinra and Ruxolitinib (overcome stage 3) Wiki | 1.00 |
drug2326 | Standard of care Wiki | 0.23 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
During SARS-Cov2 infection with serious respiratory implication and high systemic inflammation level, intravenous ANAKINRA alone or associated with RUXOLITINIB for severe cases might reduce inappropriate systemic inflammatory response, improve breathing and decrease occurrence or duration of ARDS and associated mortality.
Description: At least 3 parameters are met including CRP and/or Ferritin among: CRP: decrease > 50% Ferritinemia: decrease > 1/3 Serum creatinine: decrease > 1/3 AST/ALT: decrease > 50% Eosinophils > 50 /mm3 Lymphocytes > 1000 /mm3
Measure: Biological criteria Time: 7 days from enrolmentDescription: Number of days without mechanical ventilation
Measure: Duration of oxygen therapy (days) Time: 28 days from enrolmentDescription: Number of patients included in stage 2b
Measure: Number of intensive care units admissions Time: 28 days from enrolmentDescription: Number of days in intensive care units for patients managed in intensive care units
Measure: Number of days in intensive care units Time: 28 days from enrolmentDescription: Mortality rate
Measure: Mortality rate Time: 28 days from enrolmentDescription: Total number of days in hospital
Measure: Total number of days in hospital Time: 28 days from enrolmentDescription: Organ failure score modification (Sepsis-related Organ Failure Assessment (SOFA) score); Sofa score's minimum and maximum values are 0 and 24, the lowest score corresponds to a better outcome.
Measure: Organ failure score modification (Sepsis-related Organ Failure Assessment (SOFA) score) Time: 28 days from enrolmentDescription: Number of bacterial and/or fungal sepsis
Measure: Number of bacterial and/or fungal sepsis Time: 28 days from enrolment